Pursuant to Regulation 30 read with Schedule III Part A(A) and in compliance of Regulation 47(1)(b) of SEBI (LODR) Regulations, 2015 regarding extract of Un-Audited Standalone and Consolidated Quarter and Nine months ended on 31st December, 2024 was also approved by the Audit Committee and Board of Directors at their meeting held on Monday, 10th February, 2025. Syncom Formulations (India) has informed that it enclosed the newspaper advertisement published on 11.02.2025 in Free Press Journal English edition and Marathi (vernacular) Newspaper. The advertisement includes a Quick Response code and the weblink to access complete financial results for the said period. The above information is also available on the website of the Company.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1619.95 |
| Dr. Reddys Lab | 1315.85 |
| Cipla | 1294.75 |
| Zydus Lifesciences | 927.15 |
| Lupin | 2296.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: